EDGAR Filing Documents for 0001640334-18-000936

Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]

SEC Accession No. 0001640334-18-000936

Filing Date

2018-05-11

Accepted

2018-05-11 16:22:47

Documents

Period of Report

2017-12-31

Document Format Files

Seq	Description	Document	Type	Size
1	FORM 20-F AMENDMENT NO. 1	nymox_20fa.htm	20-F/A	900330
2	CERTIFICATION	nymox_ex12b.htm	EX-12.A	7671
3	CERTIFICATION	nymox_ex12a.htm	EX-12.B	7572
4	CERTIFICATION	nymox_ex13a.htm	EX-13.A	2207
5	CERTIFICATION	nymox_ex13b.htm	EX-13.B	2168
	Complete submission text file	0001640334-18-000936.txt		920998

Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2

Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 1-800-936-9669

NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 20-F/A | Act: 34 | File No.: 001-12033 | Film No.: 18827193
SIC: 2835 In Vitro & In Vivo Diagnostic Substances